Royalty Pharma plc (NASDAQ: RPRX) is a Healthcare company in the Medical - Pharmaceuticals industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
57.69
+0.92+1.62%
TA
Loading chart...
Snapshot
| Index | - | P/E | 23.56 | EPS (ttm) | 2.41 | Insider Own | 24.22% | Shs Outstand | 443.27M | Perf Week | -2.84% |
| Market Cap | 25.16B | Forward P/E | 10.04 | EPS next Y | 5.66 | Insider Trans | -0.42% | Shs Float | 415.02M | Perf Month | -2.05% |
| Enterprise Value | 33.31B | PEG | 6.86 | EPS next Q | - | Inst Own | - | Short Float | 2.92% | Perf Quarter | 13.09% |
| Income | 812.82M | P/S | 9.92 | EPS this Y | 198.66% | Inst Trans | - | Short Ratio | 3.28 | Perf Half Y | 28.73% |
| Sales | 2.54B | P/B | 2.58 | EPS next Y | 6.98% | ROA | 4.11% | Short Interest | 12.13M | Perf YTD | 46.92% |
| Book/sh | - | P/C | 6.76 | EPS next 5Y | 9.36% | ROE | 11.03% | 52W High | 61.42 -6.07% | Perf Year | 52.94% |
| Cash/sh | - | P/FCF | 6.73 | EPS past 3/5Y | 162.07% 7.06% | ROIC | 8.96% | 52W Low | 34.63 66.58% | Perf 3Y | 85.22% |
| Dividend Est. | 0.94 (1.63%) | EV/EBITDA | 19.43 | Sales past 3/5Y | 2.06% 2.30% | Gross Margin | 89.38% | Volatility | 3.00% 2.41% | Perf 5Y | 48.61% |
| Dividend TTM | 0.91 (1.58%) | EV/Sales | 13.14 | EPS Y/Y TTM | -7.33% | Oper. Margin | 62.34% | ATR (14) | 1.43 | Perf 10Y | - |
| Dividend Ex-Date | Aug 14, 2026 | Quick Ratio | 1.29 | Sales Y/Y TTM | 7.82% | Profit Margin | 32.15% | RSI (14) | 46.07 | Recom | 2.00 |
| Dividend Gr. 3/5Y | 5.01% 24.01% | Current Ratio | 1.29 | EPS Q/Q | 22.64% | SMA20 | -2.05% | Beta | 0.42 | Target Price | 59.50 |
| Payout | 61.76% | Debt/Eq | 0.92 | Sales Q/Q | 11.09% | SMA50 | 0.55% | Rel Volume | 1.06 | Prev Close | 56.77 |
| Employees | 100 | LT Debt/Eq | 0.88 | Earnings | Nov 04 | SMA200 | 20.88% | Avg Volume | 3.58M | Price | 57.69 |
| IPO Date | Jun 16, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 7.11% 4.91% | Net Debt/EBITDA | 4.75 | Volume | 3,805,567 | Change | 1.62% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-06-26 | Reiterated | Goldman Sachs | Buy | $59 → $66 |
| Aug-06-26 | Reiterated | Morgan Stanley | Overweight | $64 → $65 |
| Apr-21-26 | Reiterated | UBS | Buy | $49 → $57 |
| Apr-10-26 | Reiterated | Morgan Stanley | Overweight | $61 → $63 |
| Feb-27-26 | Reiterated | Seaport Global | $50 | |
| Feb-12-26 | Reiterated | Morgan Stanley | Overweight | $56 → $61 |
| Jan-30-26 | Upgrade | UBS | Neutral → Buy | $28 → $49 |
| Dec-11-25 | Reiterated | Leerink Partners | $45 | |
| Sep-30-25 | Initiated | Goldman Sachs | Buy | $51 → $42 |
| Jul-10-25 | Reiterated | Morgan Stanley | Overweight | $51 → $54 |
Latest News
Aug-05-26
12:30PM
Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcriptseekingalpha.com
10:01AM
07:00AM
Royalty Pharma reports second quarter 2026 resultsglobenewswire.com
Aug-04-26
Aug-04-2610:15AM
Aug-03-26
Aug-03-2609:56AM
08:15AM
08:01AM
Jul-29-26
Jul-29-2611:02AM
Jul-23-26
Jul-23-2604:07AM
Jul-22-26
Jul-22-2607:05AM
06:54AM
Jul-21-26
Jul-20-26
Jul-20-2608:30AM
Company
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,536 | 2,378 | 2,264 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 269 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 2,266 | 2,378 | 2,264 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 604 | 573 | 237 | — | — | — | — | — | — | |
| Research and Development | 240 | 452 | 2 | — | — | — | — | — | — | |
| Other Operating Expense | -158 | -206 | 732 | — | — | — | — | — | — | |
| Operating Income | 1,580 | 1,560 | 1,292 | — | — | — | — | — | — | |
| Interest Expense | 362 | 308 | 226 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 130 | 72 | 264 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,349 | 1,324 | 1,331 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | 815 | 771 | 859 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,349 | 1,324 | 1,331 | — | — | — | — | — | — | |
| Net Income | 815 | 771 | 859 | — | — | — | — | — | — | |
| EPS (Recurring) | 2.41 | 2.33 | 1.92 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.41 | 2.33 | 1.92 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.74 | 1.80 | 1.91 | — | — | — | — | — | — | |
| EBITDA | 1,714 | 1,636 | 1,556 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 33.16 | 21.47 | 13.36 | — | — | — | — | — | — | |
| Price To Sales Ratio | 10.12 | 7.02 | 5.03 | — | — | — | — | — | — | |
| Gross Margin | 89.35 | 100.00 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | 62.30 | 65.60 | 57.07 | — | — | — | — | — | — | |
| Net Margin | 32.14 | 32.42 | 37.94 | — | — | — | — | — | — | |
| Shares Outstanding | 445 | 432 | 446 | — | — | — | — | — | — | |
| Market Capitalization | 25,672 | 16,692 | 11,377 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Urist Marshall | EVP, Research & Investments | Jul 01 '26 | Sale | 55.88 | 9,099 | 508,454 | 0 | Jul 02 |
| Urist Marshall | EVP, Research & Investments | Jun 24 '26 | Sale | 55.18 | 9,098 | 502,067 | 9,099 | Jun 25 |
| Hite Christopher | EVP & Chairman, Partnering | Jun 23 '26 | Sale | 54.40 | 150,000 | 8,159,277 | 559,399 | Jun 25 |
| Coyne Terrance P. | EVP & CFO | May 26 '26 | Sale | 53.98 | 64,399 | 3,476,116 | 0 | May 28 |
| Urist Marshall | EVP, Research & Investments | May 20 '26 | Sale | 52.75 | 13,684 | 721,838 | 18,197 | May 21 |
| Urist Marshall | EVP, Research & Investments | May 14 '26 | Sale | 53.06 | 13,684 | 726,137 | 31,881 | May 15 |
| Norden Gregory | Director | May 14 '26 | Sale | 53.00 | 3,045 | 161,385 | 191,803 | May 15 |
| Coyne Terrance P. | EVP & CFO | Apr 28 '26 | Sale | 49.78 | 34,791 | 1,731,841 | 0 | Apr 30 |
| Coyne Terrance P. | EVP & CFO | Apr 01 '26 | Sale | 48.33 | 34,791 | 1,681,512 | 32,916 | Apr 02 |
| Coyne Terrance P. | EVP & CFO | Mar 23 '26 | Sale | 45.53 | 34,791 | 1,583,989 | 43,886 | Mar 25 |
| Coyne Terrance P. | EVP & CFO | Mar 02 '26 | Sale | 46.78 | 34,791 | 1,627,534 | 45,761 | Mar 04 |
| Coyne Terrance P. | EVP & CFO | Feb 23 '26 | Sale | 45.32 | 34,791 | 1,576,606 | 47,636 | Feb 25 |
| Coyne Terrance P. | EVP & CFO | Feb 04 '26 | Sale | 43.29 | 20,163 | 872,912 | 22,885 | Feb 04 |
| Coyne Terrance P. | EVP & CFO | Feb 03 '26 | Sale | 42.84 | 114,954 | 4,924,997 | 23,972 | Feb 04 |
| Coyne Terrance P. | EVP & CFO | Feb 02 '26 | Sale | 42.08 | 108,424 | 4,562,905 | 30,167 | Feb 04 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.